During the last session, Galectin Therapeutics Inc (NASDAQ:GALT)’s traded shares were 1.1 million, with the beta value of the company hitting 0.83. At the end of the trading day, the stock’s price was $1.29, reflecting an intraday gain of 17.27% or $0.19. The 52-week high for the GALT share is $4.27, that puts it down -231.01 from that peak though still a striking 43.41% gain since the share price plummeted to a 52-week low of $0.73. The company’s market capitalization is $94.26M, and the average intraday trading volume over the past 10 days was 2.53 million shares, and the average trade volume was 629.51K shares over the past three months.
Galectin Therapeutics Inc (NASDAQ:GALT) trade information
Galectin Therapeutics Inc (GALT) registered a 17.27% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 17.27% in intraday trading to $1.29, hitting a weekly high. The stock’s 5-day price performance is 44.93%, and it has moved by -55.36% in 30 days. Based on these gigs, the overall price performance for the year is -22.29%. The short interest in Galectin Therapeutics Inc (NASDAQ:GALT) is 5.52 million shares and it means that shorts have 42.37 day(s) to cover.
Galectin Therapeutics Inc (GALT) estimates and forecasts
Statistics show that Galectin Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Galectin Therapeutics Inc (GALT) shares have gone down -43.42% during the last six months, with a year-to-date growth rate less than the industry average at 1.35% against 16.70.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -14.30%. While earnings are projected to return 1.35% in 2025.
GALT Dividends
Galectin Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Galectin Therapeutics Inc (NASDAQ:GALT)’s Major holders
Galectin Therapeutics Inc insiders own 30.95% of total outstanding shares while institutional holders control 15.77%, with the float percentage being 22.85%. VANGUARD GROUP INC is the largest shareholder of the company, while 101.0 institutions own stock in it. As of 2024-06-30, the company held over 2.12 million shares (or 3.4143% of all shares), a total value of $4.78 million in shares.
The next largest institutional holding, with 1.56 million shares, is of BLACKROCK INC.’s that is approximately 2.5232% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.53 million.
